Dai ichi Life Insurance Company Ltd acquired a new stake in shares of Solventum Co. (NYSE:SOLV – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 8,287 shares of the company’s stock, valued at approximately $438,000.
Several other large investors have also recently added to or reduced their stakes in SOLV. Price T Rowe Associates Inc. MD acquired a new stake in shares of Solventum during the 1st quarter valued at about $5,889,000. Mitsubishi UFJ Trust & Banking Corp bought a new position in Solventum during the first quarter valued at approximately $5,747,000. CWM LLC acquired a new stake in Solventum in the second quarter valued at approximately $473,000. Great Valley Advisor Group Inc. acquired a new stake in Solventum in the second quarter valued at approximately $493,000. Finally, First Horizon Advisors Inc. bought a new stake in Solventum in the second quarter worth approximately $58,000.
Solventum Trading Up 2.6 %
Shares of SOLV stock opened at $71.80 on Tuesday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96. The stock’s 50 day simple moving average is $59.17.
Analyst Ratings Changes
Several equities research analysts recently issued reports on SOLV shares. Wells Fargo & Company reduced their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research note on Friday, August 9th. The Goldman Sachs Group upped their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Argus started coverage on Solventum in a research note on Monday, June 24th. They issued a “hold” rating on the stock. Bank of America decreased their target price on Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research report on Tuesday, June 25th. Finally, Morgan Stanley dropped their price target on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $58.25.
Get Our Latest Analysis on SOLV
Solventum Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Articles
- Five stocks we like better than Solventum
- Stock Splits, Do They Really Impact Investors?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What is a support level?
- 5 Oversold Stocks to Buy Right Now
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.